CClinicalTrials.gg
CompletedNCT03445507Dej@loUpdated Feb 4, 2021

Effectiveness of a Chat Bot for Smoking Cessation: a Pragmatic Trial in Primary Care.

An interventional study of Chat bot and Usual care in Tobacco Use Cessation, sponsored by Gerencia de Atención Primaria, Madrid. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-04.

Sponsored by Gerencia de Atención Primaria, Madrid · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
542
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effectiveness of an intervention to help people to quit smoking throughout an chat bot compared with usual assistance to increase long-term rates of nicotine abstinence in smoking outpatients with biochemical validation at 6 months.

Half of participants(control group) will receive usual care by their usual general practitioners and nurses, and the other half (intervention group) will use an evidence-based chat bot specifically designed to help people quit smoking.

Read the detailed description

An array of interventions have been shown to be both cost-effective and efficacious in helping patients quit smoking and so are included in usual care given by general practitioners and nurses. However, in the primary care setting, this sort of interventions are less common than they should be, due to many circunstances, and solutions must be found due to the huge dimensions of tobacco use challenge.

On the other hand,new kinds of information tecnology give a chance to intervene with less costs and more specific tools. Actually, there are a lot of mobile apps and other devices designed to help people to improve their health in many ways, but without scientific evidence of their effects.

This is a pragmatic, randomised, controled and multicentric clinical trial that tries to evaluate in general population the effectiveness of a chat bot that incorporates evidence based interventions and interacts by a text application instaled in patients mobile phone (intervention group).

Investigators have decided to compare with usual care delivered by the usual general practisioners and nurses of Spanish Public Health Centres, because this interventions have shown their effectiveness (control group).

Efficiency and impact on quality of life will also be compared on both groups.

02

Conditions studied

  • Tobacco Use Cessation

Keywords

  • tobacco
  • cessation
  • medical apps for smartphones
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18 years or more
  • Smoked more than one cigarette per day last month.
  • Accepts help to quit smoking next month.
  • Owns a mobile phone with the ability to install a messaging application.
  • Does not anticipate changing address in the next 6 months.
  • Understands spoken and written spanish language.
  • Accepts to participate and signs the informed consent.

Exclusion criteria

Exclusion Criteria:

  • Communicative barriers.
  • Addiction to other substances.
  • Participation in another cessation program or other clinical trial during the study period.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
542 participants (actual)

Study arms

  • Experimental
    Intervention

    Use of an evidence-based chat bot for smoking cessation

    Other: Chat bot

  • Active comparator
    Control

    Usual care (Madrid Health System Portfolio).

    Other: Usual care

Interventions

  • OtherChat bot

    Patients in intervention arm will use an evidence-based chat bot as an aid for smoking cessation

    Also known as: Intervention arm

  • OtherUsual care

    Usual care given by their usual general practitioners and nurses of primary care health centres, as defined in Public Health System Portfolio.

    Also known as: Active comparator arm

05

What researchers measure

Primary outcomes

  1. Continuous tobacco abstinence at six months biochemically validated

    Patient declares to have smoked less than five cigarettes in the last six months and have less than 10 parts per million (ppm) of carbon monoxide in exhaled air measured by a Pico+TM Smokerlyzer® cooximeter

    Time frame: Six months

Secondary outcomes

  1. Continuous tobacco abstinence at six months referred by patient

    Patient declares to have smoked less than five cigarettes in the last six months

    Time frame: Six months

  2. Descriptive improvement in patient´s quality of life

    EuroQol 5D-5L questionary score descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Patient is asked to indicate health state by ticking the box next to the most appropriate statement in each dimension. This results in a 1-digit number that expresses the level selected for that dimension. Digits can be combined into a 5-digit number that describes the patient's health state.

    Time frame: Six months

  3. Sujective improvement in patient´s quality of life

    EuroQol 5D-5L questionary score visual analogue scale (EQ VAS). EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. Can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

    Time frame: Six months

  4. QALYs

    Quality-adjusted life years

    Time frame: Six months

  5. Number of therapeutic contacts

    Number of contacts (therapist-patient or bot-patient) during the therapeutic process

    Time frame: Six months

  6. Time spent in therapy

    Total amount of time spent (in minutes) during the therapeutic process

    Time frame: Six months

06

Study locations

1 site
  • Eduardo Olano-Espinosa
    Alcorcón, Madrid 28924, Spain
07

References and documents

Publications

  • Olano-Espinosa E, Avila-Tomas JF, Minue-Lorenzo C, Matilla-Pardo B, Serrano Serrano ME, Martinez-Suberviola FJ, Gil-Conesa M, Del Cura-Gonzalez I; Dejal@ Group. Effectiveness of a Conversational Chatbot (Dejal@bot) for the Adult Population to Quit Smoking: Pragmatic, Multicenter, Controlled, Randomized Clinical Trial in Primary Care. JMIR Mhealth Uhealth. 2022 Jun 27;10(6):e34273. doi: 10.2196/34273. PubMed 35759328 ↗
  • Avila-Tomas JF, Olano-Espinosa E, Minue-Lorenzo C, Martinez-Suberbiola FJ, Matilla-Pardo B, Serrano-Serrano ME, Escortell-Mayor E; Group Dej@lo. Effectiveness of a chat-bot for the adult population to quit smoking: protocol of a pragmatic clinical trial in primary care (Dejal@). BMC Med Inform Decis Mak. 2019 Dec 3;19(1):249. doi: 10.1186/s12911-019-0972-z. PubMed 31796061 ↗

Individual participant data

Plan to share: Undecided — No Plan has been developed

08

Registry details

Key details

Study ID
NCT03445507
Lead sponsor
Gerencia de Atención Primaria, Madrid
Collaborators
Instituto de Salud Carlos III
Responsible party
Eduardo Olano (Phd in Medicine. Family and Community Medicine Specialist, Gerencia de Atención Primaria, Madrid) — Principal investigator
First posted
Feb 26, 2018
Start date
Oct 7, 2018
Primary completion
Nov 7, 2019
Completion
Dec 31, 2020
Last update
Feb 4, 2021

Study contacts

José F Ávila-Tomás, Doctor
study chair · GAP Madrid
Francisco J Ayesta-Ayesta, Doctor
study chair · Cantabria University
Francisco J Martínez-Suverbiola, Doctor
study chair · GAP Madrid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion